Pedro Miguel Lacal

1 ta ish

Istituti di Ricovero e Cura a Carattere Scientifico

1. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment

   Lucia Lisi, Pedro Miguel Lacal, Maria Martire +2

   Sharh maqola20212 iqtibos

   ABIABI:AkademIndex/2026.other.082874